马来酸曲美布汀联合阿普唑仑及双歧三联活菌治疗肠易激综合征的临床疗效观察

摘要

Objective To observe the clinical efifcacy of trimebutine maleate combined with alprazolam and biifd triple viable in the treatment of irritable bowel syndrome. Methods 120 cases with intestinal bowel syndrome were randomly divided into observation group and control group, 60 cases in each group. The control group received conventional treatment with trimebutine maleate, and on this basis, the observation group was treated with alprazolam and biifd triple viable for 4 weeks. The clinical efifcacies of the two groups were evaluated after the treatment. Results The clinical total effective rate of the observation group was 90%, and the clinical total effective rate of the observation group was 63.33%, the difference of the clinical efifcacies of the two groups was signiifcant (P<0.05). Conclusion The clinical efifcacy of rimebutine maleate combined with alprazolam and biifd triple viable in the treatment of irritable bowel syndrome is notable, the method can signiifcantly improve the efifcacy.%目的：观察马来酸曲美布汀联合阿普唑仑及双歧三联活菌治疗肠易激综合征的临床疗效。方法将120例肠易激综合征患者随机分为观察组与对照组，每组各60例。对照组采用马来酸曲美布汀进行治疗，观察组在对照组的治疗基础上，加用阿普唑仑及双歧三联活菌，两组治疗周期均为4周，治疗结束后评定疗效。结果观察组临床总有效率为90.00%，对照组临床总有效率为63.33%，两组临床疗效差异显著，具有统计学意义（P<0.05）。结论在使用马来酸曲美布汀基础上，加服阿普唑仑及双歧三联活菌治疗肠易激综合征，能显著提高疗效。